Table 4.
Subtype changes after NAC
| Basal histotype, n | Post-treatment histotype, n (%) |
||||
|---|---|---|---|---|---|
| unchanged | changed | missing data | |||
| Triple negative | 27 | 23 (95.8) | luminal B | 1 (4.2) | 3 (11.1) |
| triple negative | 2 (4.2) | 26 (35.1) | |||
| HER2 positive | 74 | 40 (83.3) | luminal A | 4 (8.3) | |
| luminal B* | 2 (4.2) | ||||
| Luminal A | 44 | 31 (77.5) | luminal B | 9 (22.5) | 4 (9.1) |
| Luminal B | 111 | 50 (53.2) | triple negative | 5 (5.3) | 17 (15.3) |
| HER2 positive | 6 (6.4) | ||||
| luminal A | 33 (35.1) | ||||
*
2/2 cases changed from HER2-positive to luminal B HER2-positive (triple positive) breast cancer.